“Avacta Reports Updated Phase 1 Clinical Data Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors. #AVA6000 is safe & well-tolerated in both study arms: every three weeks (Q3W) & every two weeks (Q2W) dosing.” #AVCT OncoAlert ESMO - Eur. Oncology #bcsm avacta.com/avacta-reports…

Congrats #ESMO24! “The results demonstrate that #AVA6000 is well-tolerated across the every 2 weeks & every 3 weeks dosing schedules w early evidence of efficacy supported by ongoing & durable RECIST responses in pts with FAPhigh disease” #AVCT OncoAlert globenewswire.com/news-release/2…

“The #AVA6000 Phase 1 Clinical data presented at #ESMO24 continue to demonstrate encouraging efficacy with several ongoing, durable responses.The observed efficacy aligns with a highly favorable safety profile” #AVCT OncoAlert ESMO - Eur. Oncology #MBC #bcsm markets.businessinsider.com/news/stocks/av…

“Astellas Presents Scientific Progress in a Phase 1/2 Trial of ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, in Patients With Advanced Solid Tumors.” Please expedite #ASP1570 for metastatic breast cancer patients #ESMO24 OncoAlert ESMO - Eur. Oncology #MBC #bcsm astellas.com/en/news/29431

“The Bria-IMT regimen is the only investigational drug we’ve seen to show these impressive survival numbers in metastatic breast cancer pts who have failed numerous prior treatments including immune check point inhibitors & ADC” $BCTX $BCTXW #ESMO24 #bcsm globenewswire.com/news-release/2…

“Patritumab deruxtecan HER3-DXd is a drug-antibody conjugate that binds an anti-HER3 antibody to chemo topoisomerase-I inhibitor. It has already been evaluated in a phaseI-II ICARUS study in pts w diff types of metastatic breast cancer” $DSNKY $MSD #ESMO24 gustaveroussy.fr/en/esmo-2024-n…

“ICARUS-BREAST01 study patritumab deruxtecan for metastatic breast cancer. With a median of 15.3 months,the RR was 53.5%,with a median duration of response of 8.7 months and median PFS of 9.4 months.Common adverse events-fatigue,nausea” $DSNKY $MSD #ESMO24 gustaveroussy.fr/en/esmo-2024-n…

“TransCode Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer. Study demonstrates that TTX-MC138 reduces tumor cell capacity for self-renewal” $RNAZ #ESMO24 ir.transcodetherapeutics.com/news-releases/…

#ESMO24 “#AVA6000 is well-tolerated across the every 2 weeks & every 3 weeks dosing schedules w early evidence of efficacy supported by ongoing & durable RECIST responses in pts with FAPhigh disease” Please expedite AVA6K for metastatic breast cancer #AVCT marketscreener.com/quote/stock/AV…

“ErSO induces complete or near-complete regression of advanced ERα+ breast cancer.ErSO/#Teq103 kills cells via necrosis pathway, a type of cell death that releases Damage Associated Molecular Pattern (DAMPs) from lysed cells” #ESMO24 OncoAlert ESMO - Eur. Oncology Vice President Kamala Harris jbc.org/article/S0021-…

“Cybrexa Therapeutics Announces Positive Final Data at #ESMO24 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors. Data of CBX-12 across 6 tumor types in TOP1-naïve patients HR+/HER2- metastatic breast cancer.” OncoAlert ESMO - Eur. Oncology globenewswire.com/news-release/2…

TransCode Therapeutics has announced the dosing of the first two patients in its Phase 1 multi center clinical trial for TTX-MC138, a first-in-class therapeutic candidate designed to treat metastatic cancers. $RNAZ #ESMO24 OncoAlert ESMO - Eur. Oncology #MBC #bcsm stocktitan.net/news/RNAZ/tran…

“TTX-MC138 is an antisense oligonucleotide conjugated to TransCode’s proprietary TTX delivery system designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancers & metastatic breast cancer” $RNAZ #ESMO24 #SABCS24 OncoAlert #bcsm Vice President Kamala Harris healthstockshub.com/news/nasdaq/rn…

Congrats Zdravka Medarova! New breakthrough, paradigm shift for metastatic breast cancer. “Phase 1 clinical trial follows evidence of delivery and pharmacodynamic activity in prior first-in-human Phase 0 clinical trial with radiolabeled TTX-MC138” #ESMO24 #SABCS24 #bcsm $RNAZ Vice President Kamala Harris

“Several additional patients have been screened for enrollment in the trial, a multicenter, open-label, dose-escalation and dose-expansion study of TTX-MC138” Please fast-track TTX-MC138 for metastatic breast cancer $RNAZ #bcsm Vice President Kamala Harris FDA Oncology NIH #MBC biospace.com/press-releases…

Innovent Delivers Oral Presentations on Clinical Data of IBI354 HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate in Advanced Metastatic Breast Cancer and Other Solid Tumors at the 2024 #ESMO24 Congress. #SABCS24 OncoAlert ESMO - Eur. Oncology #bcsm NIH Vice President Kamala Harris prnewswire.com/news-releases/…

“The data from the ABIGAIL study is a crucial step forward for pts with HR+/HER2- advanced breast cancer.The possibility of offering a chemotherapy-free alternative not only improves quality of life,but also offers new perspectives” #ESMO24 #MBC #SABCS24 medsir.org/post/medsir-pr…

“Data presented at #ESMO24 provide further proof of concept, confirming that #AVA6000 works as designed w selective targeted release of the drug warhead in the TME,resulting in lower toxicities & preliminary efficacy in cancers that over-express FAP” #AVCT research-tree.com/companies/uk/o…

“The #AVA6000 data presented at #ESMO24 continue to demonstrate encouraging efficacy with ongoing, durable responses.The observed efficacy aligns with a highly favorable safety profile including a lack of the significant cardiac toxicity” #AVCT #bcsm #MBC uk.finance.yahoo.com/news/avacta-re…

“Sonnet Bio Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors. With topline safety data expected in Q4 2024.SON-1010 is a targeted immune activation cancer therapy” $SONN #SABCS24 #bcsm stocktitan.net/news/SONN/sonn…